Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24843780)

1.

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus.

Mori H, Okada Y, Arao T, Tanaka Y.

J Diabetes Investig. 2014 May 4;5(3):313-9. doi: 10.1111/jdi.12142. Epub 2013 Sep 30.

2.

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

Hattori S.

Endocr J. 2011;58(1):69-73. Epub 2010 Dec 28.

3.

Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.

Kojima Y, Kaga H, Hayashi S, Kitazawa T, Iimura Y, Ohno M, Yoshitsugu M, Fujiwara M, Hiyoshi T.

World J Diabetes. 2013 Feb 15;4(1):8-13. doi: 10.4239/wjd.v4.i1.8.

4.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW; Gemigliptin Study 006 Group.

Diabetes Obes Metab. 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. Epub 2013 Jan 30.

PMID:
23320436
6.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

7.

Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria.

Corsonello A, Ientile R, Buemi M, Cucinotta D, Mauro VN, Macaione S, Corica F.

Am J Nephrol. 2000 May-Jun;20(3):187-92.

PMID:
10878399
9.

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S.

Tohoku J Exp Med. 2011;223(2):133-5.

10.

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A.

Metabolism. 2013 Mar;62(3):347-51. doi: 10.1016/j.metabol.2012.09.004. Epub 2012 Oct 11.

PMID:
23062489
11.

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R.

Arch Intern Med. 1998 May 11;158(9):998-1004.

PMID:
9588433
13.

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K.

Cardiovasc Diabetol. 2012 Aug 6;11:92. doi: 10.1186/1475-2840-11-92.

14.

Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.

Yanai H, Adachi H, Hamasaki H, Masui Y, Yoshikawa R, Moriyama S, Mishima S, Sako A.

J Clin Med Res. 2012 Aug;4(4):251-8. doi: 10.4021/jocmr975w. Epub 2012 Jul 20.

15.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
16.
17.

The durability of sitagliptin in elderly patients with type 2 diabetes.

Hsieh CJ, Shen FC.

Clin Interv Aging. 2014 Nov 7;9:1905-11. doi: 10.2147/CIA.S72396. eCollection 2014.

18.

Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study.

Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S, Standl E, Kofinis A, Fuller JH; EURODIAB IDDM Complications Study.

Diabet Med. 2001 Jan;18(1):59-67.

PMID:
11168343
19.

A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects.

Wang XL, Lu JM, Pan CY, Tian H, Li CL.

Diabet Med. 2005 Mar;22(3):332-5.

PMID:
15717883
20.

[Microalbuminuria and tubular reabsorption of minerals in children with type 1 diabetes mellitus].

Sufliarska A, Michalková D, Tomecková E, Sílesová J, Lenková N, Kovács L.

Bratisl Lek Listy. 1998 Jan;99(1):26-32. Slovak.

PMID:
9588076
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk